COMP <GO>
UTHR vs ROIV // OPERATING MARGIN
United Therapeutics Corporation (NASDAQ) VS. Roivant Sciences Ltd. (NASDAQ) • 15-METRIC TALLY: UTHR 8
— ROIV 3
▲ OPERATING MARGIN LEADER: UTHR
LAST: $598.72 (+0.87%) • MKT CAP: $25.46B
operating-margins
46.90%
LAST: $36.91 (-1.63%) • MKT CAP: $27.10B
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. ROIV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | ROIV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | -14.00% | +34.10 | UTHR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | -2.80% | +6.89 | UTHR | /fcf-yield <GO> |
| Operating Margin ACTIVE | 46.90% | -60.00% | +106.90 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 41.90% | -60.00% | +101.90 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | -65.00% | +75.60 | UTHR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 26.00 | -3.48 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 3/9 | +6.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.9 | 57.2 | +9.70 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.00 | -0.05 | ROIV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.8x | 28.0x | -10.20 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.46B | $27.10B | -$1.64B | ROIV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | ROIV REV | UTHR GROSS % | ROIV GROSS % | UTHR FCF | ROIV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $8.3M | 87.9% | — | $1.04B | -$758.6M |
| FY 2024 | $2.88B | $29.1M | 89.2% | — | $1.08B | -$844.0M |
| FY 2023 | $2.33B | $32.7M | — | — | $873.3M | -$766.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
ROIV // BETA 1.00